Viridian Therapeutics Inc
VRDN19.430USD
-0.190-0.97%
收盘 09/19, 16:00（美东）报价延迟15分钟
1.59B总市值
亏损市盈率 TTM
关于 Viridian Therapeutics Inc 公司
Viridian Therapeutics, Inc. 是一家生物制药公司，专注于为患有严重和罕见疾病的患者设计和开发潜在药物。该公司正在临床上推进多种治疗甲状腺眼病 (TED) 患者的候选药物。该公司正在进行两项全球 3 期临床试验 (THRIVE 和 THRIVE-2)，以评估 VRDN-001 对活动性和慢性 TED 患者的安全性和有效性。该公司专注于推进 VRDN-001 作为潜在静脉疗法，随后推进 VRDN-003 作为治疗 TED 的潜在皮下疗法。其高级项目 VRDN-001 是一种针对 IGF-1R 的差异化人源化单克隆抗体，通过静脉注射用于治疗 TED。除了 TED 产品组合外，该公司还在推进一种新型新生儿 Fc 受体 (FcRn) 抑制剂产品组合，包括 VRDN-006 和 VRDN-008，这些抑制剂有可能在多种自身免疫性疾病中得到开发。
公司简介
公司代码VRDN
公司名称Viridian Therapeutics Inc
上市日期Jun 18, 2014
CEOMr. Stephen (Steve) Mahoney
员工数量143
证券类型Ordinary Share
年结日Jun 18
公司地址221 Crescent Street
城市WALTHAM
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02453
电话16172724600
网址https://www.viridiantherapeutics.com/
公司代码VRDN
上市日期Jun 18, 2014
CEOMr. Stephen (Steve) Mahoney
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Thomas W. Beetham
Mr. Thomas W. Beetham
Chief Operating Officer
Chief Operating Officer
7.00K
+40.00%
Mr. Seth Harmon
Mr. Seth Harmon
Chief Financial Officer
Chief Financial Officer
2.61K
+161.40%
Ms. Jennifer Tousignant
Ms. Jennifer Tousignant
Chief Legal Officer
Chief Legal Officer
1.54K
--
Ms. Jennifer K. Moses
Ms. Jennifer K. Moses
Independent Director
Independent Director
--
--
Mr. Jeff Ajer
Mr. Jeff Ajer
Independent Director
Independent Director
--
--
Dr. Sarah Gheuens, M.D., Ph.D.
Dr. Sarah Gheuens, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Arlene M. Morris
Ms. Arlene M. Morris
Independent Director
Independent Director
--
--
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen (Steve) Mahoney
Mr. Stephen (Steve) Mahoney
President, Chief Executive Officer, Director (Principal Executive Officer)
President, Chief Executive Officer, Director (Principal Executive Officer)
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Thomas W. Beetham
Mr. Thomas W. Beetham
Chief Operating Officer
Chief Operating Officer
7.00K
+40.00%
Mr. Seth Harmon
Mr. Seth Harmon
Chief Financial Officer
Chief Financial Officer
2.61K
+161.40%
Ms. Jennifer Tousignant
Ms. Jennifer Tousignant
Chief Legal Officer
Chief Legal Officer
1.54K
--
Ms. Jennifer K. Moses
Ms. Jennifer K. Moses
Independent Director
Independent Director
--
--
Mr. Jeff Ajer
Mr. Jeff Ajer
Independent Director
Independent Director
--
--
Dr. Sarah Gheuens, M.D., Ph.D.
Dr. Sarah Gheuens, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明细
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
72.00K
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
13.11%
Deep Track Capital LP
6.59%
Commodore Capital LP
5.97%
BlackRock Institutional Trust Company, N.A.
5.84%
The Vanguard Group, Inc.
5.50%
其他
62.99%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
13.11%
Deep Track Capital LP
6.59%
Commodore Capital LP
5.97%
BlackRock Institutional Trust Company, N.A.
5.84%
The Vanguard Group, Inc.
5.50%
其他
62.99%
股东类型
持股股东
占比
Hedge Fund
44.95%
Investment Advisor
38.32%
Investment Advisor/Hedge Fund
21.22%
Venture Capital
9.84%
Research Firm
1.95%
Pension Fund
0.74%
Private Equity
0.55%
Bank and Trust
0.42%
Corporation
0.11%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
368
94.63M
115.87%
-12.44M
2025Q1
387
93.96M
114.21%
-15.28M
2024Q4
381
93.18M
114.36%
-9.55M
2024Q3
354
88.84M
112.43%
+6.26M
2024Q2
331
71.47M
112.09%
-12.60M
2024Q1
329
71.87M
114.62%
-2.66M
2023Q4
309
61.41M
117.06%
+4.73M
2023Q3
286
52.92M
124.61%
-2.63M
2023Q2
276
50.12M
119.65%
-257.35K
2023Q1
259
46.00M
110.76%
-2.29M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
10.52M
12.78%
+350.50K
+3.45%
Mar 31, 2025
Deep Track Capital LP
5.38M
6.53%
+857.71K
+18.96%
Mar 31, 2025
Commodore Capital LP
4.30M
5.22%
+700.00K
+19.44%
Apr 04, 2025
BlackRock Institutional Trust Company, N.A.
5.10M
6.19%
-74.84K
-1.45%
Mar 31, 2025
The Vanguard Group, Inc.
4.55M
5.52%
-31.95K
-0.70%
Mar 31, 2025
Kynam Capital Management LP
4.70M
5.71%
+1.37M
+41.30%
Mar 31, 2025
VR Adviser, LLC
3.88M
4.72%
--
--
Mar 31, 2025
Fairmount Funds Management LLC
3.46M
4.2%
+14.10K
+0.41%
Jun 10, 2025
Tang Capital Management, LLC
2.79M
3.39%
+300.00K
+12.03%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.63M
1.98%
+357.70K
+28.08%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
1.32%
Simplify Propel Opportunities ETF
1.3%
ALPS Medical Breakthroughs ETF
0.86%
SPDR S&P Biotech ETF
0.34%
iShares Micro-Cap ETF
0.28%
Direxion Daily S&P Biotech Bull 3X Shares
0.22%
Nuveen ESG Small-Cap ETF
0.09%
Avantis US Small Cap Equity ETF
0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.08%
iShares Russell 2000 Growth ETF
0.06%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比1.32%
Simplify Propel Opportunities ETF
占比1.3%
ALPS Medical Breakthroughs ETF
占比0.86%
SPDR S&P Biotech ETF
占比0.34%
iShares Micro-Cap ETF
占比0.28%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.22%
Nuveen ESG Small-Cap ETF
占比0.09%
Avantis US Small Cap Equity ETF
占比0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0.08%
iShares Russell 2000 Growth ETF
占比0.06%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
公告日期
类型
比率
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
